Skip to main content
Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

EU Medicines Agency Reverses Course on Eli Lilly's Alzheimer Drug

Summary by EURACTIV
The EU's medicines regulator said it would approve the treatment for a limited group of patients, citing concerns over side effects

2 Articles

EURACTIVEURACTIV
Lean Left

EU medicines agency reverses course on Eli Lilly's Alzheimer drug

The EU's medicines regulator said it would approve the treatment for a limited group of patients, citing concerns over side effects

·Brussels, Belgium
Read Full Article
endpoints.newsendpoints.news

CHMP backs Lilly’s Alzheimer’s drug in certain patients, Gilead’s twice-yearly HIV prevention shot, among others

CHMP endorses 13 new medicines including Lilly's Alzheimer's drug Kisunla and Gilead's HIV preventive lenacapavir, while rejecting three drugs including Sarepta's Elevidys.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Left
100% Left

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

endpoints.news broke the news in on Friday, July 25, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Alzheimer's Disease icon

Alzheimer's Disease

HIV icon

HIV

Eli Lilly icon

Eli Lilly

European Union icon

European Union

Medical icon

Medical

Brussel icon

Brussel

News
For You
SearchBlindspotLocal